Effect of treatment with intranasal corticosteroid and oral antihistamine on cytokine profiles of peripheral blood mononuclear cells of patients with allergic rhinitis sensitive to chenopodium album.
Patients with allergic rhinitis (AR) show increased production of the Th2-related cytokines. Almost always, intranasal corticosteroid (INC) and antihistamine are used as routine therapy of AR. This study was performed to determine the in vitro secretion of cytokines profiles of PBMCs in patients with AR sensitive to Chenopodium album (Ch.a) pollens before and after treatment with INC (Fluticasone propionate) and oral antihistamine (Loratadine). PBMCs of 20 patients with AR, were tested in vitro for cytokine production. These cells were stimulated with natural or recombinant Ch.a. The levels of IL-4, IL-13 and IFN-, were measured in supernatants of cultured cell 96h after stimulation using ELISA. The PBMCs of 20 normal individuals were also similarly treared for comparison of results. The production of IL-4 by the patients' cells stimulated with either Ch.a or rCh.a was significantly higher than normal levels before therapy (p=0.04 and p=0.02, respectively). After therapy, a significant decrease in production of IL-4 and a significant increase in production of IL-10 were found in PBMCs stimulated with natural Ch.a, in comparison to the results before stimulation (p=0.03 for IL-4; p=0.04 for IL-10). Similarly, these results were seen in the production of IL-4 and IL-10 stimulated with rCh.a allergen after therapy in comparison to the results before stimulation (p=0.01 for IL-4; p=0.03 for IL-10). This study suggests INC (Fluticasone propionate) and oral antihistamine (Loratadine) have the capacity to inhibit the production of IL-4 and shift Th2/Th1 responses, probably due to increase the level of immunoregulatory IL-10. Therefore, it could be concluded that therapy with INC and antihistamine has pharmacologic and immunologic therapeutic effects on AR patients.
Department of Immunology, Tehran University of Medical Sciences, Tehran, Iran.
Shokrollah
S
Farrokhi
Tahereh
T
Mousavi
Saba
S
Arshi
Naser
N
Javahertarash
Abdolreza
A
Varasteh
Reza
R
Falak
Nima
N
Rezaei
Alireza
A
Salekmoghadam
D000328:Adult; D000485:Allergens / Q000276:immunology; D000730:Androstadienes / Q000627:therapeutic use*; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D027463:Chenopodium album / Q000276:immunology; D016207:Cytokines / Q000276:immunology*; D005260:Female; D000068298:Fluticasone; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D018793:Interleukin-13 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism*; D017336:Loratadine / Q000627:therapeutic use*; D008297:Male; D011058:Pollen / Q000276:immunology; D012220:Rhinitis / Q000188:drug therapy* / Q000276:immunology; D018417:Th1 Cells / Q000187:drug effects / Q000378:metabolism; D018418:Th2 Cells / Q000187:drug effects / Q000378:metabolism; D055815:Young Adult
D000485:Allergens; D000730:Androstadienes; D018926:Anti-Allergic Agents; D016207:Cytokines; D018793:Interleukin-13; D016753:Interleukin-10; D015847:Interleukin-4; D017336:Loratadine; D007371:Interferon-gamma; D000068298:Fluticasone